Revolution Medicines, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Revolution Medicines announced FDA acceptance of daraxonrasib NDA for previously treated metastatic pancreatic cancer (based on Phase 3 RASolute 302 showing OS/PFS benefit), launched Expanded Access Program with 2,000+ patients, and achieved U.S. commercial readiness. In April-May 2026, the company raised $2.225B ($1.725B common stock + $500M convertible notes at 0.50% due 2033) and received $250M from Royalty Pharma. Cash position reached $3.9B (vs. $2.0B at year-end 2025). Q2 2026 operating expenses surged: R&D $395M (vs. $224M YoY), G&A $110M (vs. $41M YoY); net loss $644M (vs. $248M YoY), including $151M warrant fair-value charge. FY2026 guidance: $2.1–$2.2B operating expenses.
Why this rating
Meaningful catalyst: first NDA filing validates lead program; $2.2B capital raise extends runway substantially relative to ~$6.7B market cap (~33% capital raise). Significant execution risk ahead (FDA approval, commercial launch, Phase 3 readouts 2027).
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.